Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. (PSTX) priced its initial public offering on Jul 10, 2020 at $16.00 per share, raising $224M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $989.1M. BofA Securities was lead-left underwriter, joined by Piper Sandler and William Blair. Cooley advised the company and Latham & Watkins advised the underwriters.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company using proprietary gene engineering platforms to build cell and gene therapies. Its core technologies include the non-viral piggyBac DNA Modification System, the Cas-CLOVER gene editing system, and nanoparticle- and AAV-based gene delivery.

Status

IPO

Ticker

PSTX

Exchange

Nasdaq Global Select

Priced

Jul 10, 2020

IPO price

$16.00

Raised

$224M

Market cap at IPO price

$989.1M

First filed

Jan 4, 2019

Underwriters

BofA Securities, Piper Sandler and William Blair

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.